Dianthus Therapeutics (DNTH) Income from Continuing Operations (2017 - 2025)
Dianthus Therapeutics' (DNTH) quarterly Income from Continuing Operations came in at 165165000.0 in Q3 2025, down 121.75% year-on-year from 759220784.11 in Q3 2024, and down 226.61% quarter-over-quarter from 50570000.0 in Q2 2025.
Dianthus Therapeutics (DNTH) Income from Continuing Operations (2017 - 2025) Analysis & Trends
Dianthus Therapeutics' Income from Continuing Operations history runs 9 years deep, the most recent figure standing at 165165000.0 for Q3 2025.
- On a quarterly basis, Income from Continuing Operations fell 121.75% year-over-year to 165165000.0 in Q3 2025; TTM through Sep 2025 was 287101000.0, a 66.37% decrease from a year earlier, with the FY2024 full-year figure at 266104000.0, down 55.24% from the prior year.
- Income from Continuing Operations retreated to 165165000.0 in Q3 2025 per DNTH's latest filing, from 50570000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 7094000.0 in Q1 2023 and bottomed at 165165000.0 in Q3 2025.
- The 5-year median for Income from Continuing Operations is 24717000.0 (2021), against an average of 36515526.32.
- Across the five-year window, Income from Continuing Operations jumped 77.8% in 2023 and sank 453.5% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 28049000.0 in 2021, then soared by 64.16% to 10053000.0 in 2022, then plunged by 49.89% to 15068000.0 in 2023, then sank by 61.57% to 24345000.0 in 2024, then slumped by 578.43% to 165165000.0 in 2025.
- Per Business Quant, the three latest DNTH Income from Continuing Operations figures stand at 165165000.0 (Q3 2025), 50570000.0 (Q2 2025), and 47021000.0 (Q1 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Dianthus Therapeutics | 3.92 Bn | 3.51 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -165.17 Mn |
| Jun 30, 2025 | -50.57 Mn |
| Mar 31, 2025 | -47.02 Mn |
| Dec 31, 2024 | -24.35 Mn |
| Sep 30, 2024 | -74.48 Mn |
| Jun 30, 2024 | -65.00 Mn |
| Mar 31, 2024 | -18.02 Mn |
| Dec 31, 2023 | -15.07 Mn |
| Sep 30, 2023 | -22.50 Mn |
| Jun 30, 2023 | -11.74 Mn |
| Mar 31, 2023 | -7.09 Mn |
| Dec 31, 2022 | -10.05 Mn |
| Sep 30, 2022 | -18.61 Mn |
| Jun 30, 2022 | -29.85 Mn |
| Mar 31, 2022 | -31.95 Mn |
| Dec 31, 2021 | -28.05 Mn |
| Sep 30, 2021 | -23.80 Mn |
| Jun 30, 2021 | -24.72 Mn |
| Mar 31, 2021 | -25.77 Mn |
| Dec 31, 2020 | -92.73 Mn |